Gensight Biologics (XPAR:SIGHT) OCF Margin %: -3,050.45% (As of Dec. 2025)


What is Gensight Biologics OCF Margin %?

Gensight Biologics XPAR:SIGHT -3.64% OCF Margin % is -3,050.45% as of Dec. 2025. The stock has 8 warning signs investors should review. Among 959 Biotechnology companies, Gensight Biologics ranks worse than 99.79% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Gensight Biologics's Cash Flow from Operations for the six months ended in Dec. 2025 was €-6.71 Mil. Gensight Biologics's Revenue for the six months ended in Dec. 2025 was €0.22 Mil. Therefore, Gensight Biologics's OCF Margin % for the quarter that ended in Dec. 2025 was -3,050.45%.

As of today, Gensight Biologics's current OCF Yield % is -49.19%.

The historical rank and industry rank for Gensight Biologics's OCF Margin % or its related term are showing as below:

XPAR:SIGHT' s OCF Margin % Range Over the Past 10 Years
Min: -917000   Med: -1307.24   Max: -324.85
Current: -917000

During the past 13 years, the highest OCF Margin % of Gensight Biologics was -324.85%. The lowest was -917000.00%. And the median was -1307.24%.

XPAR:SIGHT's OCF Margin % is ranked worse than
99.79% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs XPAR:SIGHT: -917000.00

Gensight Biologics OCF Margin % Related Terms

Gensight Biologics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Gensight Biologics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gensight Biologics OCF Margin % Chart

Gensight Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -324.85 -1,307.24 -1,946.57 -862.47 -917,000.00

Gensight Biologics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,987.63 -675.71 -1,354.00 1,122.83 -3,050.45

XPAR:SIGHT vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, Gensight Biologics's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gensight Biologics OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gensight Biologics's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Gensight Biologics's OCF Margin % falls into.


Gensight Biologics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Gensight Biologics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-9.17/0.001
=-917,000.00 %

Gensight Biologics's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-6.711/0.22
=-3,050.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -3,050.45% mean?
Gensight Biologics (XPAR:SIGHT) has a OCF Margin % of -3,050.45% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Gensight Biologics and its competitors. According to the industry distribution chart, Gensight Biologics ranks #957 out of 959 companies in the Biotechnology industry, placing it in the top 99.8%.
Is Gensight Biologics' OCF Margin % too high?
Gensight Biologics' current OCF Margin % is -3,050.45%. Based on the distribution chart, Gensight Biologics ranks #957 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Gensight Biologics' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #957 out of 959 companies for OCF Margin %. This places Gensight Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Gensight Biologics and its competitors. Gensight Biologics's current OCF Margin % is -3,050.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (XPAR:SIGHT) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.08 — trading 98.8% above its estimated fair value. The current OCF Margin % is -3,050.45%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Gensight Biologics (XPAR:SIGHT), the current OCF Margin % is -3,050.45% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gensight Biologics Business Description

Address 74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.